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Abstract
Background: The knowledge of the individual genetic “status” in the prenatal era is particularly relevant in the case
of positive family history for genetic diseases, in advanced maternal age and in the general screening for foetal
abnormalities. In this context, here, we report an innovative molecular assay which utilizes the cell-free foetal DNA
(cffDNA) as a source for the early and fast detection of the foetal sex. The study involved 132 pregnant women in
their first 3 months of pregnancy, who agreed to give a blood sample. All the collected samples were immediately
subjected to the separation of the plasma, which was utilized for the extraction of the cffDNA. Successively, the
extracted cffDNA was analysed by a quantitative PCR (qPCR) method based on Plexor-HY chemistry, which is able
to simultaneously identify, quantify and discriminate the autosomal DNA from the sex-linked DNA.
Results: Overall, the Plexor-HY assay demonstrated to be sensitive and specific for the determination of low-
template DNA, such as the cffDNA. In fact, the Plexor-HY assay has been successfully performed in all the samples,
identifying 70 males and 62 females. As the foetal sex can be provided in 120 min just by utilizing a maternal
blood sample as cffDNA source, the assay represents a very fast, safe and non-invasive prenatal method.
Conclusions: The possibility of determining the foetal sex in the early prenatal life consents the application of our
assay as a helpful screening test for subjects and families at risk of sex-linked disorders. Moreover, the early knowledge
of the foetal sex may be of great help even for the specialist, who might promptly advise the patients concerning the
foetal risk of inheriting sex-linked disorders and the clinical utility of performing an invasive prenatal diagnosis.
Background
Prenatal diagnosis represents a fundamental step for the
identification of genetic pathologies, either caused by
numeric and structural chromosomal aberrations, inher-
ited DNA mutations (Mendelian disorders) or malfor-
mative parts [1]. In fact, prenatal knowledge of the
genetic “status” of an individual is particularly relevant
in the case of a positive family history for genetic diseases
and advanced maternal age as well as in the general
screening of foetal abnormalities [2]. A prenatal diagnosis
is essentially composed of two steps: gynaecologic/genetic
counselling and gynaecologic/laboratory practice. In par-
ticular, gynaecologic/genetic counselling is a service that
provides information about the pros and cons of prenatal
approaches in terms of the risk, waiting times and reliabil-
ity of the results [3]. The gynaecologic/laboratory practice
includes both prenatal techniques (invasive and non-
invasive) and genetic approaches (karyotyping and
molecular assays) [4]. To date, the invasive approaches
(amniocentesis and chorionic villous sampling, CVS) are
considered to be the gold standard techniques for prenatal
testing, although these procedures can sometimes be fatal
for the foetus (~0.2–0.5 %) [5, 6].
The non-invasive prenatal tests (NIPTs) allow for the
gathering of information about the “status” of the foetus
without affecting the structures that are primarily in-
volved in foetal development/life [7]. The NIPT methods
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are therefore safer in terms of abortion risk relative to
the invasive methods. The NIPTs can be distinguished in
diagnostic (ultrasonography) and non-diagnostic (bio-
chemical screening and the analysis of the cell-free foetal
DNA (cffDNA)) approaches [8, 9].
Analysis of cffDNA is the most recent non-diagnostic
NIPT method. Although the source of cffDNA is not
completely understood, it may originate from fragments
of apoptotic placental cells (trophoblast cells) [10]. The
cffDNA is highly detectable in the maternal blood, either
in the plasma or in serum fractions at the fifth week of
pregnancy [11, 12]. The concentration of cffDNA in-
creases during the weeks of gestation and ranges from
3.3 to 69.4 to 76.9 to 769 copies/ml (accounting for 3 to
6 % of the free DNA present in the maternal circulation
[13]. Given its characteristics, cffDNA represents as an
excellent source of DNA that is applicable to the early
prenatal tests [12]. On this subject, many innovative
next-generation sequencing (NGS) platforms have been
recently designed to evaluate chromosomal or DNA al-
terations with massive and high-throughput approaches.
In addition, the NGS techniques are also able to discrim-
inate foetal sex with high-accuracy and sensitive results.
However, the effective application of NGS in clinical
practice is limited by elevated costs in terms of the time
and equipment required for the whole analysis [14]. Sex
determination is, in fact, usually performed through the
application of PCR-based techniques, either standard
PCR or real-time PCR [15].
Knowledge of foetal sex can provide helpful informa-
tion on the risk of X-linked diseases (Duchenne’s dys-
trophy, fragile X disorder and haemophilia), metabolic
conditions associated with development of ambiguous
external genitalia and risk of congenital adrenal hyper-
plasia [15–17].
In this context, we describe a 3-h molecular assay that
utilizes cffDNA as a source for the early detection of
foetal sex.
Methods
This study was previously approved by the ethics commit-
tee of the University of Rome “Tor Vergata”. The study
was performed according to the tenets of the Declaration
of Helsinki. The samples were recruited from the Depart-
ment of Biomedicine and Prevention, Section of Obstetrics
and Gynaecology at “Tor Vergata” University Hospital
Rome, Italy. All of the participants were also subjected to
invasive prenatal diagnosis (IPD) through traditional
methods, in particular, amniocentesis or CVS (indications
for IPD were advanced maternal age or abnormal results
of NIPTs). The clinical data of the recruited samples are
reported in Additional file 1. Signed informed consent
was obtained from all of the participants before the
blood sample collection. Peripheral blood samples
(10 ml) were collected from 132 pregnant women
during their first 3 months of pregnancy (from the
12th to 14th gestational weeks, in particular 44
women per class). The collected samples were utilized
for the extraction of the cffDNA.
The cffDNA was analysed with a fluorescence-based
quantitative PCR (qPCR) method to simultaneously iden-
tify, quantify and discriminate the autosomal DNA from
the sex-linked DNA. The qPCR procedure was performed
utilizing Plexor-HY chemistry (Promega), which exploits
specific primers for the amplification of Y-chromosomal
DNA, human autosomal DNA and an internal positive
control (IPC). Additionally, the Plexor-HY assay provided
a “standard DNA”, which is a synthetic DNA (concen-
trated to 50 ng/μl) that is necessary to quantify the un-
known samples (through the realization of a “standard
curve” obtained by the serial dilution of the standard
DNA from 10 to 0.032 ng/μl).
The specificity and reliability of the qPCR reaction
is assessed by the generation of a dissociation curve
and the calculation of the melting temperature (Tm)
of the products after the amplification [18]. In our
study, the dissociation curve and the Tm were crucial
for the interpretation of the results and the correct
determination of foetal sex.
The foetal sex of the samples was established according
to the presence/absence of a fluorescence signal, which
was emitted only in the presence of a Y-chromosomal
DNA substrate. Therefore, the only sex-linked DNA that
can be quantified is from the Y-chromosomal DNA and it
is correlated with the amount of emitted-fluorescence.
The quantity of X-chromosomal DNA cannot be specific-
ally detected because the Plexor-HY system does not con-
tain the primers for its amplification. The female sex is
thereby deducible on the basis of the missing fluores-
cence (instead of the detection of a fluorescent signal)
as well as of a “flat” dissociation curve (due to the
absence of amplification). This aspect actually repre-
sents a limit of the method, which can be partially
overcome by comparing the unknown samples with
the control samples (with known sex).
Concerning the amplification/quantification of the
autosomic DNA, it can be performed with all of the
samples independently from gender.
All the technical details of the cffDNA extraction and
of the Plexor-HY assay for the foetal sex determination
have been reported in the Additional file 2.
Results
The molecular assay for the simultaneous determin-
ation of foetal sex and quantification of the autoso-
mic/sex-linked DNA has been successfully performed
in all 132 samples, identifying 70 males and 62 fe-
males. Figure 1a represents the melting curve from
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the amplification of the Y-chromosomal DNA (male
foetal sex) sample with its specific Tm (82.1 °C) and
fluorescence intensity. Figure 1b depicts the “flat” dis-
sociation curve resulting from the absence of a fluor-
escent signal (no amplification) and indicates the
presence of X-chromosomal DNA (female foetal sex).
Our method has been validated in terms of specifi-
city and sensitivity for the determination of foetal sex
by comparing our results with those obtained from
traditional prenatal tests (i.e., amniocentesis, CVS and
ultrasonography) on the same samples. The compari-
son between Plexor-HY technology and the common
procedures showed a 100 % concordance, with no
false positive/negative results (Table 1). In addition,
the sensitivity of the Plexor-HY assay has been evalu-
ated by the calculation of the minimum detectable
concentration (limit of detection (LOD)) of cffDNA.
The LOD has been measured testing cffDNA concen-
trations included in a range from 10 to 0.0001 ng/μl.
These experiments showed that the LOD for Plexor-
HY assay is 0.0001 ng/μl ± 0.5.
As expected, the amount of autosomic/sex-linked
cffDNA was found to be increased from the 12th to the
14th gestational week. In fact, the autosomic DNA
amount ranged from 1.42 × 10−2 to 1.86 × 10−1 pg/μl,
while the sex-linked DNA (Y-chromosomal DNA) con-
centration varied from 0.009 to 0.09 pg/μl throughout
the gestational weeks taken into consideration.
Discussion
Overall, the Plexor-HY assay was shown to be sensitive
and specific for the determination of low-template DNA,
such as cffDNA. Despite other qPCR methods, Plexor
chemistry based on the incorporation of modified nucle-
otides, multicopy gene targets and generation of a dis-
sociation curve made the assay highly performant and
reliable for the analysis of cffDNA.
As the foetal sex can be determined within 120 min by
utilizing a maternal blood sample as a DNA source, the
assay is a very fast, safe and non-invasive prenatal
method. In Fig. 2, the workflow depicts the different op-
erational phases (counselling and laboratory practice)
that characterize the test for early foetal sex determin-
ation by our method.
Given the possibility of applying the Plexor-HY assay for
the identification of foetal sex in the first trimester (12th
gestational week), it may represent a helpful screening test
for inherited X-linked disorders, such as Duchenne’s mus-
cular dystrophy (DMD). The DMD is an X-linked reces-
sive disorder with an incidence of 1/3300 male newborns.
The clinical picture of the disease is characterized by the
atrophy and progressive degeneration of the muscular fi-
bres that lead to a deficit of muscular strength in the first
3–5 years of life. Concerning the genetic picture of the
disease, several mutations in the DMD gene (Xp21.2, co-
difying for the dystrophin protein) have been identified as
major causes of the pathologic phenotype.
Fig. 1 a Result interpretation of the Plexor-HY assay on cffDNA. The detection of the fluorescence signal is indicative of the presence of Y-
chromosomal DNA substrate (male foetal sex). b Result interpretation of the Plexor-HY assay on cffDNA. In this case, the absence of the
fluorescence signal is interpreted as the presence of X-chromosomal DNA substrate (female foetal sex)
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On this subject, we evaluated the clinical utility of the
Plexor-HY System in two families with a positive history
for DMD. The blood samples of the two pregnant women
were taken at their 12th gestational week to extract and
analyse the cffDNA. The application of the Plexor-HY
technology led to the identification of one female foetus
and one male foetus, respectively. Given these results, the
early prenatal identification of the foetal sex was useful to
provide an initial indication about the risk of inheriting
DMD. The results obtained by the Plexor-HY assay have
been successively confirmed with the DNA analysis per-
formed by an invasive procedure (CVS). These results
suggested that our method may be employed to reassure
patients about the risk of inheriting DMD in relation to
foetal sex and eventually avoid further invasive proce-
dures. However, it is important to remind that the test is
able to determine the foetal sex, while the effective diag-
nosis of DMD can only be done by the traditional molecu-
lar diagnostic approaches.
The determination of foetal sex by non-invasive cffDNA
analysis may be thus validated as a rapid, safe and early
prenatal screening test for subjects and families at risk of
X-linked disorders, metabolic condition associated with
ambiguous development of external genitalia and risk of
congenital adrenal hyperplasia. This approach may be
really advantageous for both the woman and the foetus,
since the risk of abortion caused by the traditional invasive
techniques is effectively abolished.
In this context, genetic counselling plays a fundamental
role in providing the right support to the patient, both in
the pre- and post-test phases. In fact, counselling before
the test is necessary to elucidate the utility of the early
prenatal screening of foetal sex, while post-test counselling
has to explain the result of the test to enable the patient/
couple to consciously take her/their own decision.
In conclusion, here, we report a 3-h molecular assay that
utilizes cffDNA as the source for the early detection of the
foetal sex. Our results showed that Plexor chemistry with
cffDNA is a reproducible, sensitive, robust and non-invasive
method for prenatal screening of the gender. Moreover, the
early knowledge of foetal sex may be of great help even for
the specialist, who might promptly advise the patients about
the risks (sex-linked disorders) for the foetus and the
clinical utility of performing an invasive prenatal diagnosis.
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The study has been approved by the Ethics Committee of
the University of Rome “Tor Vergata”. The study was per-
formed according to the tenets of the Declaration of
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Table 1 Concordance analysis of the foetal sex detected by cffDNA and the traditional prenatal approaches
Gestational week (wa)
of blood sampling
cffDNAb CVSc Amniocentesis Concordance
(%)(Foetal sex) (Foetal sex) (Foetal sex)
12 44 32 12 100
(Md = 24; Fe = 20) (M = 17; F = 15) (M = 7; F = 5)
13 44 20 24 100
(M = 22; F = 22) (M = 8; F = 12) (M = 14; F = 10)
14 44 9 35 100






Fig. 2 Workflow for the foetal sex determination by the Plexor-HY
assay on cffDNA
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